Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2475-2487

  Pozo, Natividad ^a   Zahonero, Cristina ^a   Fernández, Paloma ^b   Liñares, Jose M ^a   Ayuso, Angel ^c   Hagiwara, Masatoshi ^d   Pérez, Angel ^e   Ricoy, Jose R ^e   Hernández Laín, Aurelio ^e   Sepúlveda, Juan M ^e   Sánchez Gómez, Pilar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c Hospital de Madrid   (Spain)

^d KYOTO UNIVERSITY   (Japan)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN P53; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HARMINE; HUMANS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878611414     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI63623     Document Type: Article

References (63)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: International Agency for Research on Cancer; 2007.
2. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010;116(17):3988-3999.
4. Singh SK, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401.
5. Galli R, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-7021.
6. Yuan X, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004; 23(58):9392-9400.
7. Sutter R, Yadirgi G, Marino S. Neural stem cells, tumour stem cells and brain tumours: dangerous relationships? Biochim Biophys Acta. 2007; 1776(2):125-137.
8. Nicolis SK. Cancer stem cells and "stemness" genes in neuro-oncology. Neurobiol Dis. 2007;25(2):217-229.
9. Dirks PB. Brain tumor stem cells: the cancer stem cell hypothesis writ large. Mol Oncol. 2010;4(5):420-430.
10. Lee J, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391-403.
11. Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
12. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol Cancer. 2011;10:128.
13. Wang R, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468(7325):829-833.
14. Ricci-Vitiani L, et al. Tumour vascularization via endothelial differentiation of glioblastoma stemlike cells. Nature. 2010;468(7325):824-828.
15. Stiles CD and Rowitch DH. Glioma stem cells: a midterm exam. Neuron. 2008;58(6):832-846.
16. Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol. 2010;3(1):37-52.
17. Soeda A, et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem. 2008;283(16):10958- 10966.
18. Jin X, et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011;71(22):7125-7134.
19. Mazzoleni S, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010;70(19):7500-7513.
20. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol. 2005;74(1):77-86.
21. Peereboom DM, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93-99.
22. van den Bent MJ, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
23. Mellinghoff IK, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012-2024.
24. Haas-Kogan DA, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005; 97(12):880-887.
25. Aranda S, Laguna A, de la LS. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J. 2011; 25(2):449-462.
26. Tejedor FJ and Hammerle B. MNB/DYRK1A as a multiple regulator of neuronal development. FEBS J. 2011;278(2):223-235.
27. Wegiel J, Gong CX, Hwang YW. The role of DYRK1A in neurodegenerative diseases. FEBS J. 2011; 278(2):236-245.
28. Ferron SR, et al. Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell. 2010;7(3):367-379.
29. Marti E, et al. Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Res. 2003;964(2):250-263.
30. Wegiel J, et al. Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res. 2004;1010(1-2):69- 80.
31. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol. 1996;149(1):29-35.
32. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
33. Laguna A, et al. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev Cell. 2008;15(6):841-853.
34. Ogawa Y, et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun. 2010;1:86.
35. Coates GH, Cox B. Harmine tremor after brain monoamine oxidase inhibition in the mouse. Eur J Pharmacol. 1972;18(2):284-286.
36. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2004;39(1):29-36.
37. Ramnarain DB, et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 2006;66(2):867-874.
38. Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis. 2008;11(1):53-62.
39. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res. 2009;7(7):1000-1012.
40. Squatrito M, Holland EC. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res. 2011; 71(18):5945-5949.
41. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60(5):1383-1387.
42. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010; 7(9):493-507.
43. Vivanco I, et al. Differential sensitivity of gliomaversus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012; 2(5):458-471.
44. Barkovich KJ, et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov. 2012;2(5):450-457.
45. Jun HJ, et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene. 2012; 31(25):3039-3050.
46. Weihua Z, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008;13(5):385-393.
47. Coker KJ, Staros JV, Guyer CA. A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis. Proc Natl Acad Sci U S A. 1994;91(15):6967-6971.
48. Ewald JA, Wilkinson JC, Guyer CA, Staros JV. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp Cell Res. 2003; 282(2):121-131.
49. Friedman LM, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A. 2005;102(6):1915-1920.
50. Adayev T, Wegiel J, Hwang YW. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch Biochem Biophys. 2011; 507(2):212-218.
51. Levkowitz G, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12(23):3663-3674.
52. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 2010;70(12):4789-4794.
53. Mizoguchi M, Nutt CL, Louis DN. Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma. Neurogenetics. 2004;5(1):81-82.
54. Guo D, et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 2006;111(3):238-246.
55. Ye F, et al. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol. 2009;94(2):183-194.
56. Ying H, et al. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A. 2010;107(15):6912-6917.
57. Aranda S, Alvarez M, Turro S, Laguna A, de la LS. Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A. Mol Cell Biol. 2008;28(19):5899-5911.
58. Kim HJ, Taylor LJ, Bar-Sagi D. Spatial regulation of EGFR signaling by Sprouty2. Curr Biol. 2007; 17(5):455-461.
59. Rubin C, Zwang Y, Vaisman N, Ron D, Yarden Y. Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. J Biol Chem. 2005; 280(10):9735-9744.
60. Barbachano A, et al. SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene. 2010;29(34):4800-4813.
61. Ivliev AE, 't Hoen PA, Sergeeva MG. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Cancer Res. 2010; 70(24):10060-10070.
62. Hamsa TP, Kuttan G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol. 2010; 649(1-3):64-73.
63. Ferron SR, Andreu-Agullo C, Mira H, Sanchez P, Marques-Torrejon MA, Farinas I. A combined ex/in vivo assay to detect effects of exogenously added factors in neural stem cells. Nat Protoc. 2007; 2(4):849-859.